Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
Japan has scrapped the acquisition of 40M doses of AstraZeneca's (NASDAQ:AZN) COVID vaccines, Reuters reported citing a health ministry official who spoke in the parliament. Japan had initially agreed to purchase 120M doses, with the majority made locally by Daiichi Sankyo (OTCPK:DSKYF) ...
AstraZeneca (NASDAQ:AZN) is scheduled to announce Q4 earnings results on Thursday, February 10th, before market open. The consensus EPS Estimate is $0.99 (-7.5% Y/Y) and the consensus Revenue Estimate is $11.08B (+49.5% Y/Y). Over the last 2 years, AZN has beaten EPS estimates 88% of the time...
Daiichi Sankyo Company, Limited (DSKYF) Q3 2022 Earnings Conference Call January 31, 2022 01:00 AM ET Company Participants Hiroyuki Okuzawa - Director, Executive Officer, Head of Corporate Planning & Management Division, CFO Wataru Takasaki - Executive Officer, Head of R&D Div. Confer...
An analysis of phase 3 data on AstraZeneca (AZN -0.1%) and Daiichi Sankyo's (OTCPK:DSKYF -1.9%) Enhertu (am-trastuzumab deruxtecan-nxki) found it demonstrated a higher progression-free survival ("PFS") and objective response rate ("ORR") in some patient subgroups compared to trastuzumab emtan...
Daiichi Sankyo Company Limited (DSKYF) Q2 2022 Earnings Conference Call October 29, 2021 2:30 AM ET Company Participants Sunao Manabe - President, Group CEO & Representative Director Wataru Takasaki - Executive Officer and Head of R&D Division Conference Call Participants Kazuaki Hash...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with this event. For further details see: Daiichi Sankyo Company Limited (DSKYF) ESMO 2021Virtual Congress Presentation - Slideshow
Daiichi Sankyo Company Limited (DSKYF) Q1 2022 Results Conference Call July 30, 2021 2:00 AM ET Company Participants Hiroyuki Okuzawa - Head of Corporate Planning & Management Division, CFO Wataru Takasaki - Head of R&D Division Conference Call Participants Kazuaki Hashiguchi - Daiwa ...
Daiichi Sankyo Co. (OTCPK:DSKYF): Q1 Non-GAAP EPS of ¥18.36. Revenue of ¥264B (+11.9% Y/Y) Press Release For further details see: Daiichi Sankyo Co. reports Q1 results
Roland Magnusson/iStock Editorial via Getty Images Today, AstraZeneca (AZN) and Daiichi Sankyo Company (DSKYF), (DSNKY) announced that the first patient was dosed in a Phase 3 trial designed to evaluate ENHERTU (trastuzumab deruxtecan) in a subset of patients with gastric or gastroesophageal ...
Dr_Microbe/iStock via Getty Images Today's up to $3B development and commercialization deal from Bristol-Myers Squibb (BMY) for Eisai's (ESALY) for MORAb-202 is putting antibody drug conjugates ("ADCs"), which some feel is the future of cancer therapeutics, into the spotlight. The o...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...